

Biobanks Market – Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, Segmented By Type (Disease Oriented Biobanks, Population Based Biobanks, Tissue Biobanks, Others), By Sample Type (Blood Products, Biological Fluids, Nucleic Acid, Cell Lines, Others), By Application (Therapeutics, Drug Discovery, Clinical Diagnostics, Clinical Research), By End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others), By Region, and By Competition, 2019-2029F

<https://marketpublishers.com/r/BE4FCB7B69E0EN.html>

Date: April 2024

Pages: 184

Price: US\$ 4,900.00 (Single User License)

ID: BE4FCB7B69E0EN

Abstracts

Global Biobanks Market was valued at USD 75.34 billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 8.54% through 2029. The Global Biobanks Market is experiencing substantial growth driven by increasing demand for high-quality biological samples for research, clinical trials, and personalized medicine initiatives. Biobanks serve as repositories for storing various types of biological specimens, including blood, tissues, cells, and DNA, along with associated data such as medical histories and lifestyle information. These repositories play a crucial role in advancing biomedical research, enabling scientists to access large and diverse collections of samples for studying diseases, identifying biomarkers, and developing new therapeutics. One of the key drivers fueling the growth of the Global Biobanks Market is the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions. The need for well-characterized and annotated biospecimens from diverse patient populations is essential for

understanding disease mechanisms, discovering novel therapeutic targets, and evaluating treatment responses. Additionally, advancements in biobanking technologies, including automation, robotics, and data management systems, are enhancing the efficiency, scalability, and quality of biobanking operations. The increasing adoption of precision medicine approaches and personalized healthcare strategies is driving the demand for biospecimens with detailed molecular and clinical annotations. Biobanks play a pivotal role in supporting precision medicine initiatives by providing researchers and clinicians with access to comprehensive collections of samples for genotype-phenotype correlations, pharmacogenomics studies, and patient stratification efforts. As a result, the Global Biobanks Market is poised for continued expansion, offering significant opportunities for biobanking organizations, healthcare institutions, and life sciences companies to contribute to biomedical research and therapeutic innovation.

Key Market Drivers

Rising Demand for High-Quality Biological Samples

The Global Biobanks Market is experiencing a surge in demand for high-quality biological samples driven by the increasing need for reliable biospecimens in biomedical research, drug development, and clinical applications. High-quality biological samples are essential for studying disease mechanisms, identifying biomarkers, and developing novel therapeutics, making biobanks indispensable resources in the life sciences industry. One of the primary factors fueling the rising demand for high-quality biological samples is the growing emphasis on precision medicine and personalized healthcare. Precision medicine approaches aim to tailor medical treatments to individual patients based on their genetic makeup, lifestyle factors, and environmental influences. As such, there is a heightened need for biospecimens with detailed molecular and clinical annotations to support genotype-phenotype correlations, pharmacogenomics studies, and patient stratification efforts. The increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions is driving the demand for biospecimens for disease research and therapeutic development. Biobanks provide researchers and clinicians with access to diverse collections of well-characterized biological samples from various patient populations, enabling the investigation of disease etiology, progression, and treatment responses. Advancements in biobanking technologies have also contributed to the rising demand for high-quality biological samples. Automation, robotics, and data management systems have improved the efficiency, scalability, and reliability of biobanking operations, enabling biobanks to store, process, and manage large volumes of biospecimens and associated data with

greater precision and consistency. The increasing adoption of biobanking practices in translational research, clinical trials, and population health studies further drives the demand for high-quality biological samples. Biobanks play a crucial role in facilitating collaborations between academia, industry, and healthcare sectors, fostering innovation and accelerating the development of new diagnostics, therapeutics, and personalized medicine approaches. The rising demand for high-quality biological samples underscores the critical role of biobanks in advancing biomedical research and improving patient care, driving growth and expansion in the Global Biobanks Market.

Advancements in Biobanking Technologies

Advancements in biobanking technologies have revolutionized the landscape of the Global Biobanks Market, enhancing the efficiency, scalability, and reliability of biological sample storage, management, and analysis. These technological innovations have propelled the field of biobanking forward, enabling biobanks to meet the growing demands of researchers, clinicians, and pharmaceutical companies for high-quality biospecimens. One significant advancement in biobanking technology is the implementation of automation and robotics systems. Automated sample handling and processing equipment streamline biobanking workflows, reducing human error, increasing throughput, and improving sample integrity. Robotics platforms enable precise and consistent sample retrieval, aliquoting, and storage, ensuring sample quality and minimizing contamination risks. The advancements in data management systems have revolutionized biobank operations by facilitating efficient sample tracking, inventory management, and data integration. Electronic laboratory information management systems (LIMS) and biobanking software solutions enable real-time monitoring of sample locations, conditions, and associated metadata, ensuring traceability and compliance with regulatory requirements. The innovations in sample preservation and storage technologies have expanded the capabilities of biobanks to store diverse types of biological specimens under optimal conditions. State-of-the-art cryopreservation methods, such as automated liquid nitrogen storage systems and vapor-phase nitrogen freezers, ensure long-term sample viability while minimizing degradation and sample loss. The emerging technologies such as blockchain and artificial intelligence (AI) hold promise for enhancing data security, privacy, and analysis capabilities within the biobanking sector. Blockchain-based systems enable secure and transparent management of sample-related transactions and data sharing, while AI algorithms offer powerful tools for data analysis, pattern recognition, and predictive modeling in biobanking research. The advancements in biobanking technologies are driving innovation, efficiency, and collaboration within the Global Biobanks Market, empowering researchers and clinicians to accelerate biomedical research, drug

discovery, and personalized medicine initiatives. Continued investments in technology development and infrastructure are expected to further propel the growth and evolution of the biobanking industry in the years to come.

Growing Prevalence of Chronic Diseases

The growing prevalence of chronic diseases is a significant driver shaping the trajectory of the Global Biobanks Market. Chronic diseases, including cancer, cardiovascular disorders, diabetes, and neurological conditions, pose significant public health challenges worldwide, contributing to a substantial burden of morbidity and mortality. As the incidence of chronic diseases continues to rise globally, there is an increasing need for high-quality biological samples to support research efforts aimed at understanding disease mechanisms, identifying biomarkers, and developing effective treatments. Biobanks play a crucial role in addressing the growing prevalence of chronic diseases by providing researchers, clinicians, and pharmaceutical companies with access to diverse collections of well-characterized biological specimens. These biospecimens, which include blood, tissues, cells, and DNA samples, are essential for studying disease etiology, progression, and treatment responses. For instance, biobanks enable researchers to investigate genetic and environmental factors contributing to the development of chronic diseases, facilitating the discovery of novel biomarkers for early detection, prognosis, and personalized treatment approaches. Additionally, biobanks support translational research efforts by providing access to clinical samples from large and diverse patient populations, enabling the validation of new diagnostic tools and therapeutic interventions. The biobanks play a critical role in supporting longitudinal studies and population health research initiatives aimed at identifying risk factors, trends, and disparities in chronic disease prevalence and outcomes. By collecting and analyzing longitudinal data and biospecimens from individuals over time, biobanks contribute valuable insights into disease trajectories, treatment responses, and long-term health outcomes. The growing prevalence of chronic diseases underscores the importance of biobanking in advancing biomedical research, improving clinical care, and addressing global health challenges. Continued investments in biobank infrastructure, technology, and collaboration are essential for meeting the increasing demand for high-quality biological samples and driving innovation in chronic disease prevention, diagnosis, and treatment.

Key Market Challenges

Sample Quality and Integrity

Sample quality and integrity are paramount in the Global Biobanks Market to ensure the reliability and reproducibility of research findings and clinical applications. Challenges related to sample quality and integrity include the risk of degradation over time, variability in sample collection and processing methods, and the potential for contamination. Maintaining sample quality starts with rigorous adherence to standardized protocols for sample collection, processing, and storage. Proper handling techniques, such as ensuring appropriate temperature control and using preservatives, are essential to minimize degradation and maintain sample integrity. The robust quality control measures, including regular sample monitoring, testing for contamination, and validation of sample identity, are crucial for ensuring the accuracy and reliability of stored samples. Biobanks invest in state-of-the-art infrastructure and employ advanced technologies to safeguard sample quality and integrity. These include automated sample handling systems, stringent quality assurance protocols, and comprehensive data management systems to track sample provenance and ensure compliance with regulatory requirements. By prioritizing sample quality and integrity, biobanks can enhance the utility and value of their repositories, enabling researchers, clinicians, and pharmaceutical companies to access high-quality biological specimens for a wide range of biomedical research and clinical applications.

Data Management and Integration

In the Global Biobanks Market, effective data management and integration are critical for maximizing the utility of biological samples and associated data for research and clinical applications. Biobanks collect and store vast amounts of data, including clinical, genetic, and molecular information, alongside biological specimens. Managing and integrating this diverse array of data presents several challenges. One challenge is the need to establish robust data management systems capable of handling large volumes of data while ensuring security, privacy, and compliance with regulatory requirements. Biobanks must implement advanced data storage, retrieval, and sharing mechanisms to facilitate efficient data management across different research projects and collaborations. The integrating data from disparate sources poses challenges related to data harmonization, standardization, and interoperability. Biobanks must adopt standardized data formats, ontologies, and metadata standards to facilitate data integration and enable cross-study comparisons. Advancements in technologies such as cloud computing, artificial intelligence, and blockchain offer opportunities to enhance data management and integration capabilities within the biobanking sector. These technologies enable real-time data processing, analysis, and sharing, improving data accessibility, collaboration, and knowledge discovery. By addressing challenges related to data management and integration, biobanks can unlock the full potential of their

repositories, enabling researchers, clinicians, and policymakers to access comprehensive datasets for advancing biomedical research, drug discovery, and personalized medicine initiatives. Collaborative efforts to establish best practices, standards, and infrastructure for data management and integration are essential for driving innovation and accelerating progress in the field of biobanking.

Key Market Trends

Expansion of Disease-specific Biobanks

The expansion of disease-specific biobanks is a significant trend shaping the Global Biobanks Market. These biobanks focus on collecting, storing, and managing biospecimens from patients with specific diseases or conditions, catering to the specialized needs of researchers and clinicians in targeted research areas. One key driver behind the expansion of disease-specific biobanks is the growing recognition of the heterogeneity and complexity of diseases. By focusing on specific diseases or conditions, these biobanks enable researchers to access well-characterized samples that are relevant to their research interests, facilitating more targeted investigations into disease mechanisms, biomarker discovery, and therapeutic development. The disease-specific biobanks play a crucial role in advancing precision medicine initiatives. By collecting biospecimens from patients with specific diseases, these biobanks contribute to the development of personalized treatment strategies tailored to individual patients' genetic makeup, lifestyle factors, and disease characteristics. For example, cancer biobanks collect tumor samples from patients with different types and stages of cancer, enabling researchers to identify biomarkers associated with treatment response and prognosis and develop targeted therapies. Disease-specific biobanks foster collaboration among researchers, clinicians, and patient advocacy groups focused on specific diseases. By providing a centralized repository of biospecimens and associated clinical data, these biobanks facilitate knowledge sharing, data analysis, and resource pooling, accelerating research progress and improving patient outcomes. The expansion of disease-specific biobanks reflects a growing emphasis on precision medicine, personalized healthcare, and collaborative research initiatives within the Global Biobanks Market. Continued investment in disease-specific biobanking infrastructure, technology, and collaboration is essential for addressing the complex challenges associated with various diseases and driving innovation in biomedical research and clinical care...

Shift towards Virtual Biobanking

The Global Biobanks Market is witnessing a notable shift towards virtual biobanking, a trend characterized by the sharing of data and biospecimens across multiple biobanks and research institutions. Virtual biobanking offers several advantages over traditional, centralized biobanking models, including increased collaboration, data sharing, and resource optimization. One of the key drivers behind the shift towards virtual biobanking is the growing recognition of the need for large, diverse datasets to support biomedical research and personalized medicine initiatives. By enabling researchers to access a wider range of samples and data from multiple biobanks, virtual biobanking facilitates more comprehensive and robust analyses, leading to a deeper understanding of disease mechanisms, biomarker discovery, and therapeutic development. The virtual biobanking promotes collaboration and knowledge exchange among researchers, clinicians, and institutions worldwide. By sharing data and resources, researchers can leverage each other's expertise, infrastructure, and sample collections, accelerating research progress and maximizing the impact of limited resources. Virtual biobanking enables biobanks to overcome logistical and ethical challenges associated with sample sharing. By implementing standardized protocols, data sharing agreements, and quality control measures, virtual biobanks ensure the ethical and responsible use of biospecimens and associated data while protecting patient privacy and confidentiality. Virtual biobanking facilitates data integration and analysis across different research projects and institutions, enabling researchers to perform cross-study comparisons, meta-analyses, and validation studies more efficiently. This approach enhances the reproducibility and generalizability of research findings and promotes transparency and accountability within the scientific community. The shift towards virtual biobanking reflects a growing emphasis on collaboration, data sharing, and innovation in the Global Biobanks Market. Continued investment in virtual biobanking infrastructure, technology, and governance frameworks is essential for realizing the full potential of this transformative approach in advancing biomedical research and improving patient care.

Segmental Insights

Type Insights

Based on type, disease-oriented biobanks segment dominated the Global Biobanks Market in 2023. This is ascribed to the specialized focus on collecting biospecimens from patients with specific diseases or conditions. This targeted approach facilitates in-depth research into disease mechanisms, biomarker discovery, and therapeutic development, catering to the diverse needs of researchers and clinicians. Disease-oriented biobanks enable precision medicine initiatives by providing well-characterized samples relevant to individual diseases, driving advancements in personalized

healthcare. Additionally, the collaborative nature of disease-oriented biobanks fosters partnerships among researchers, clinicians, and patient advocacy groups, further enhancing their prominence in the biobanking landscape.

Application Insights

Based on application, drug discovery segment dominated the Global Biobanks Market in 2023. This is ascribed due to the increasing demand for high-quality biological samples to support drug development efforts. Biobanks provide researchers with access to diverse collections of well-characterized biospecimens, enabling the identification of novel drug targets, evaluation of drug efficacy and safety, and optimization of therapeutic interventions. Additionally, advancements in biobanking technologies and collaborations between biobanks and pharmaceutical companies further bolster the role of biobanks in drug discovery. The potential to accelerate the drug development process and bring new treatments to market drives significant investment and focus on the Drug Discovery segment within the Global Biobanks Market.

Regional Insights

North America leads the Global Biobanks Market, due to several factors. The region boasts advanced healthcare infrastructure and significant investments in biomedical research, fostering the establishment of numerous high-quality biobanks. North America is home to many leading pharmaceutical and biotechnology companies, driving demand for biological samples for drug discovery and development. The supportive regulatory frameworks and strong academic and research institutions contribute to the region's leadership in biobanking. The presence of a highly skilled workforce and a culture of innovation further strengthens North America's position in the Global Biobanks Market. Overall, the combination of robust infrastructure, industry expertise, regulatory support, and research capabilities makes North America a dominant player in the biobanking landscape.

Key Market Players

Danaher Corporation

Merck KgaA

Becton, Dickinson, and Company

Avantor, Inc.

Thermo Fisher Scientific, Inc

Tecan Trading AG

QIAGEN N.V.

Hamilton Company

ProMedDx, LLC

ISENET Biobanking S.r.l

Report Scope:

In this report, the Global Biobanks Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Biobanks Market,By Type:

oDisease Oriented Biobanks

oPopulation Based Biobanks

oTissue Biobanks

oOthers

Global Biobanks Market,By Sample Type:

oBlood Products

oBiological Fluids

oNucleic Acid

oCell Lines

oOthers

Global Biobanks Market,ByApplication:

oTherapeutics

oDrug Discovery

oClinical Diagnostics

oClinical Research

Global Biobanks Market,ByEnd User:

oAcademic Research Institutes

oPharmaceutical Biotechnology Companies

oHospitals Clinics

oOthers

·Global Biobanks Market, By Region:

oNorth America

United States

Canada

Mexico

oEurope

France

United Kingdom

Italy

Germany

Spain

oAsia-Pacific

China

India

Japan

Australia

South Korea

oSouth America

Brazil

Argentina

Colombia

oMiddle East Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Biobanks Market.

Available Customizations:

Global Biobanks Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1.PRODUCT OVERVIEW

- 1.1.Market Definition
- 1.2.Scope of the Market
 - 1.2.1.Markets Covered
 - 1.2.2.Years Considered for Study
 - 1.2.3.Key Market Segmentations

2.RESEARCH METHODOLOGY

- 2.1.Objective of the Study
- 2.2.Baseline Methodology
- 2.3.Key Industry Partners
- 2.4.Major Association and Secondary Sources
- 2.5.Forecasting Methodology
- 2.6.Data Triangulation Validation
- 2.7.Assumptions and Limitations

3.EXECUTIVE SUMMARY

- 3.1.Overview of the Market
- 3.2.Overview of Key Market Segmentations
- 3.3.Overview of Key Market Players
- 3.4.Overview of Key Regions/Countries
- 3.5.Overview of Market Drivers, Challenges, Trends

4.VOICE OF CUSTOMER

5.GLOBAL BIOBANKS MARKET OUTLOOK

- 5.1.Market Size Forecast
 - 5.1.1.By Value
- 5.2.Market Share Forecast
 - 5.2.1.By Type (Disease Oriented Biobanks, Population Based Biobanks, Tissue Biobanks, Others)
 - 5.2.2.By Sample Type (Blood Products, Biological Fluids, Nucleic Acid, Cell Lines, Others)

5.2.3.By Application (Therapeutics, Drug Discovery, Clinical Diagnostics, Clinical Research)

5.2.4.By End User (Academic Research Institutes, Pharmaceutical Biotechnology Companies, Hospitals Clinics, Others)

5.2.5.By Region

5.2.6.By Company (2023)

5.3.Market Map

5.3.1.By Type

5.3.2.By Sample Type

5.3.3.By Application

5.3.4.By End User

5.3.5.By Region

6.ASIA PACIFIC BIOBANKS MARKET OUTLOOK

6.1.Market Size Forecast

6.1.1.By Value

6.2.Market Share Forecast

6.2.1.By Type

6.2.2.By Sample Type

6.2.3.By Application

6.2.4.By End User

6.2.5.By Country

6.3.Asia Pacific: Country Analysis

6.3.1.China Biobanks Market Outlook

6.3.1.1.Market Size Forecast

6.3.1.1.1.By Value

6.3.1.2.Market Share Forecast

6.3.1.2.1.By Type

6.3.1.2.2.By Sample Type

6.3.1.2.3.By Application

6.3.1.2.4.By End User

6.3.2.India Biobanks Market Outlook

6.3.2.1.Market Size Forecast

6.3.2.1.1.By Value

6.3.2.2.Market Share Forecast

6.3.2.2.1.By Type

6.3.2.2.2.By Sample Type

6.3.2.2.3.By Application

- 6.3.2.2.4.By End User
- 6.3.3.Japan Biobanks Market Outlook
 - 6.3.3.1.Market Size Forecast
 - 6.3.3.1.1.By Value
 - 6.3.3.2.Market Share Forecast
 - 6.3.3.2.1.By Type
 - 6.3.3.2.2.By Sample Type
 - 6.3.3.2.3.By Application
 - 6.3.3.2.4.By End User
- 6.3.4.South Korea Biobanks Market Outlook
 - 6.3.4.1.Market Size Forecast
 - 6.3.4.1.1.By Value
 - 6.3.4.2.Market Share Forecast
 - 6.3.4.2.1.By Type
 - 6.3.4.2.2.By Sample Type
 - 6.3.4.2.3.By Application
 - 6.3.4.2.4.By End User
- 6.3.5.Australia Biobanks Market Outlook
 - 6.3.5.1.Market Size Forecast
 - 6.3.5.1.1.By Value
 - 6.3.5.2.Market Share Forecast
 - 6.3.5.2.1.By Type
 - 6.3.5.2.2.By Sample Type
 - 6.3.5.2.3.By Application
 - 6.3.5.2.4.By End User

7.EUROPE BIOBANKS MARKET OUTLOOK

- 7.1.Market Size Forecast
 - 7.1.1.By Value
- 7.2.Market Share Forecast
 - 7.2.1.By Type
 - 7.2.2.By Sample Type
 - 7.2.3.By Application
 - 7.2.4.By End User
 - 7.2.5.By Country
- 7.3.Europe: Country Analysis
 - 7.3.1.France Biobanks Market Outlook
 - 7.3.1.1.Market Size Forecast

- 7.3.1.1.1.By Value
- 7.3.1.2.Market Share Forecast
 - 7.3.1.2.1.By Type
 - 7.3.1.2.2.By Sample Type
 - 7.3.1.2.3.By Application
 - 7.3.1.2.4.By End User
- 7.3.2.United Kingdom Biobanks Market Outlook
 - 7.3.2.1.Market Size Forecast
 - 7.3.2.1.1.By Value
 - 7.3.2.2.Market Share Forecast
 - 7.3.2.2.1.By Type
 - 7.3.2.2.2.By Sample Type
 - 7.3.2.2.3.By Application
 - 7.3.2.2.4.By End User
- 7.3.3.Italy Biobanks Market Outlook
 - 7.3.3.1.Market Size Forecast
 - 7.3.3.1.1.By Value
 - 7.3.3.2.Market Share Forecast
 - 7.3.3.2.1.By Type
 - 7.3.3.2.2.By Sample Type
 - 7.3.3.2.3.By Application
 - 7.3.3.2.4.By End User
- 7.3.4.Germany Biobanks Market Outlook
 - 7.3.4.1.Market Size Forecast
 - 7.3.4.1.1.By Value
 - 7.3.4.2.Market Share Forecast
 - 7.3.4.2.1.By Type
 - 7.3.4.2.2.By Sample Type
 - 7.3.4.2.3.By Application
 - 7.3.4.2.4.By End User
- 7.3.5.Spain Biobanks Market Outlook
 - 7.3.5.1.Market Size Forecast
 - 7.3.5.1.1.By Value
 - 7.3.5.2.Market Share Forecast
 - 7.3.5.2.1.By Type
 - 7.3.5.2.2.By Sample Type
 - 7.3.5.2.3.By Application
 - 7.3.5.2.4.By End User

8.NORTH AMERICA BIOBANKS MARKET OUTLOOK

8.1.Market Size Forecast

8.1.1.By Value

8.2.Market Share Forecast

8.2.1.By Type

8.2.2.By Sample Type

8.2.3.By Application

8.2.4.By End User

8.2.5.By Country

8.3.North America: Country Analysis

8.3.1.United States Biobanks Market Outlook

8.3.1.1.Market Size Forecast

8.3.1.1.1.By Value

8.3.1.2.Market Share Forecast

8.3.1.2.1.By Type

8.3.1.2.2.By Sample Type

8.3.1.2.3.By Application

8.3.1.2.4.By End User

8.3.2.Canada Biobanks Market Outlook

8.3.2.1.Market Size Forecast

8.3.2.1.1.By Value

8.3.2.2.Market Share Forecast

8.3.2.2.1.By Type

8.3.2.2.2.By Sample Type

8.3.2.2.3.By Application

8.3.2.2.4.By End User

8.3.3.Mexico Biobanks Market Outlook

8.3.3.1.Market Size Forecast

8.3.3.1.1.By Value

8.3.3.2.Market Share Forecast

8.3.3.2.1.By Type

8.3.3.2.2.By Sample Type

8.3.3.2.3.By Application

8.3.3.2.4.By End User

9.SOUTH AMERICA BIOBANKS MARKET OUTLOOK

9.1.Market Size Forecast

- 9.1.1.By Value
- 9.2.Market Share Forecast
 - 9.2.1.By Type
 - 9.2.2.By Sample Type
 - 9.2.3.By Application
 - 9.2.4.By End User
 - 9.2.5.By Country
- 9.3.South America: Country Analysis
 - 9.3.1.Brazil Biobanks Market Outlook
 - 9.3.1.1.Market Size Forecast
 - 9.3.1.1.1.By Value
 - 9.3.1.2.Market Share Forecast
 - 9.3.1.2.1.By Type
 - 9.3.1.2.2.By Sample Type
 - 9.3.1.2.3.By Application
 - 9.3.1.2.4.By End User
 - 9.3.2.Argentina Biobanks Market Outlook
 - 9.3.2.1.Market Size Forecast
 - 9.3.2.1.1.By Value
 - 9.3.2.2.Market Share Forecast
 - 9.3.2.2.1.By Type
 - 9.3.2.2.2.By Sample Type
 - 9.3.2.2.3.By Application
 - 9.3.2.2.4.By End User
 - 9.3.3.Colombia Biobanks Market Outlook
 - 9.3.3.1.Market Size Forecast
 - 9.3.3.1.1.By Value
 - 9.3.3.2.Market Share Forecast
 - 9.3.3.2.1.By Type
 - 9.3.3.2.2.By Sample Type
 - 9.3.3.2.3.By Application
 - 9.3.3.2.4.By End User

10.MIDDLE EAST AND AFRICA BIOBANKS MARKET OUTLOOK

- 10.1.Market Size Forecast
 - 10.1.1.By Value
- 10.2.Market Share Forecast
 - 10.2.1.By Type

- 10.2.2.By Sample Type
- 10.2.3.By Application
- 10.2.4.By End User
- 10.2.5.By Country
- 10.3.MEA: Country Analysis
 - 10.3.1.South Africa Biobanks Market Outlook
 - 10.3.1.1.Market Size Forecast
 - 10.3.1.1.1.By Value
 - 10.3.1.2.Market Share Forecast
 - 10.3.1.2.1.By Type
 - 10.3.1.2.2.By Sample Type
 - 10.3.1.2.3.By Application
 - 10.3.1.2.4.By End User
 - 10.3.2.Saudi Arabia Biobanks Market Outlook
 - 10.3.2.1.Market Size Forecast
 - 10.3.2.1.1.By Value
 - 10.3.2.2.Market Share Forecast
 - 10.3.2.2.1.By Type
 - 10.3.2.2.2.By Sample Type
 - 10.3.2.2.3.By Application
 - 10.3.2.2.4.By End User
 - 10.3.3.UAE Biobanks Market Outlook
 - 10.3.3.1.Market Size Forecast
 - 10.3.3.1.1.By Value
 - 10.3.3.2.Market Share Forecast
 - 10.3.3.2.1.By Type
 - 10.3.3.2.2.By Sample Type
 - 10.3.3.2.3.By Application
 - 10.3.3.2.4.By End User
 - 10.3.4.Egypt Biobanks Market Outlook
 - 10.3.4.1.Market Size Forecast
 - 10.3.4.1.1.By Value
 - 10.3.4.2.Market Share Forecast
 - 10.3.4.2.1.By Type
 - 10.3.4.2.2.By Sample Type
 - 10.3.4.2.3.By Application
 - 10.3.4.2.4.By End User

11.MARKET DYNAMICS

11.1.Drivers

11.2.Challenges

12.MARKET TRENDS DEVELOPMENTS

12.1.Recent Developments

12.2.Product Launches

12.3.Mergers Acquisitions

13.GLOBAL BIOBANKS MARKET: SWOT ANALYSIS

14.PORTER'S FIVE FORCES ANALYSIS

14.1.Competition in the Industry

14.2.Potential of New Entrants

14.3.Power of Suppliers

14.4.Power of Customers

14.5.Threat of Substitute Product

15.COMPANY PROFILE

15.1.Danaher Corporation

15.1.1.Business Overview

15.1.2.Company Snapshot

15.1.3.Products Services

15.1.4.Financials (In case of listed)

15.1.5.Recent Developments

15.1.6.SWOT Analysis

15.2.Merck KGaA

15.3.Becton, Dickinson, and Company

15.4.Avantor, Inc.

15.5.Thermo Fisher Scientific, Inc

15.6.Tecan Trading AG

15.7.QIAGEN N.V.

15.8.Hamilton Company

15.9.ProMedDx, LLC

15.10.ISENET Biobanking S.r.l

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US DISCLAIMER

I would like to order

Product name: Biobanks Market – Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, Segmented By Type (Disease Oriented Biobanks, Population Based Biobanks, Tissue Biobanks, Others), By Sample Type (Blood Products, Biological Fluids, Nucleic Acid, Cell Lines, Others), By Application (Therapeutics, Drug Discovery, Clinical Diagnostics, Clinical Research), By End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Others), By Region, and By Competition, 2019-2029F

Product link: <https://marketpublishers.com/r/BE4FCB7B69E0EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BE4FCB7B69E0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970